The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

重症肌无力（myasthenia gravis，MG）是由自身抗体介导的获得性神经-肌肉接头（neuromuscular junction，NMJ）传递障碍的自身免疫性疾病。乙酰胆碱受体（AChR ...

重症肌无力（Myasthenia gravis，MG）是一种神经肌肉接头疾病，通过评分量表，可以对患者的病情严重程度进行定量评估，从而更为直观地评价患者病情 ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

来自一项小规模临床试验的证据表明，一种称为CAR-T细胞的先进血癌免疫疗法的改进形式经调整后可能能够用于治疗重症肌无力（myasthenia gravis），即 ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

Myasthenia gravis is an autoimmune disorder causing muscle weakness that worsens with activity and improves with rest. It ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

Astrazeneca plc seems on the way to expanding its presence in myasthenia gravis (MG) with positive “high-level” results from ...

AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits ...